TOP2A and neoplasm: Although the number of samples in our study is limited, the portion of tumor samples that contain HER2/TOP2A allelic instability in the TN and ERPR+ group (75 % and 38 %, respectively) roughly corresponded to the AC-based chemotherapy response rates found within these groups (85 % and 47 %, respectively) [37].